A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer

被引：0
|
作者：
Hurwitz, H [1 ]
Fernando, N [1 ]
Yu, DH [1 ]
Morse, M [1 ]
Blobe, G [1 ]
Gockerman, J [1 ]
Odogwu, L [1 ]
Mahon, M [1 ]
Truax, R [1 ]
Franklin, A [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：285 / 285
页数：1
相关论文
共 50 条
  • [1] A Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer
    Wong, Nan Soon
    Fernando, Nishan H.
    Nixon, Andrew B.
    Cushman, Stephanie
    Aklilu, Mebea
    Bendell, Johanna C.
    Morse, Michael A.
    Blobe, Gerard C.
    Ashton, Jill
    Pang, Herbert
    Hurwitz, Herbert I.
    ANTICANCER RESEARCH, 2011, 31 (01) : 255 - 261
  • [2] A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer.
    Fernando, N
    Yu, D
    Morse, M
    Blobe, G
    Odogwu, L
    Crews, J
    Polito, A
    Honeycutt, W
    Franklin, A
    Hurwitz, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 260S - 260S
  • [3] A phase ii study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer
    Bendell, J.
    Fernando, N.
    Morse, M.
    Blobe, G.
    Yu, D.
    Sutton, L.
    Vaccaro, G.
    Honeycutt, W.
    Franklin, A.
    Hurwitz, H.
    ANNALS OF ONCOLOGY, 2006, 17 : 67 - 67
  • [4] A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer.
    Bendell, J. C.
    Fernando, N.
    Morse, M.
    Blobe, G.
    Yu, D.
    Sutton, L.
    Schaffer, S.
    Honeycutt, W.
    Franklin, A.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 156S - 156S
  • [5] Capecitabine and oxaliplatin (XELOX) in combination with bevacizumab in the treatment of metastatic colorectal cancer: results of a phase II trial
    Bendell, J.
    Yu, D.
    Hurwitz, H.
    Morse, M.
    Blobe, G.
    Gockerman, J.
    Odogwu, L.
    Mahon, M.
    Truax, R.
    Fernando, N.
    EJC SUPPLEMENTS, 2005, 3 (02): : 189 - 189
  • [6] A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
    Uronis, Hope E.
    Bendell, Johanna C.
    Altomare, Ivy
    Blobe, Gerard C.
    Hsu, S. David
    Morse, Michael A.
    Pang, Herbert
    Zafar, S. Yousuf
    Conkling, Paul
    Favaro, Justin
    Arrowood, Christy C.
    Cushman, Stephanie M.
    Meadows, Kellen L.
    Brady, John C.
    Nixon, Andrew B.
    Hurwitz, Herbert I.
    ONCOLOGIST, 2013, 18 (03): : 271 - 272
  • [7] A Phase II Study of Oxaliplatin, Dose-intense Capecitabine, and High-dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer
    Wong, Nan Soon
    Fernando, Nishan H.
    Bendell, Johanna C.
    Morse, Michael A.
    Blobe, Gerard C.
    Honeycutt, Wanda
    Pang, Herbert
    Hurwitz, Herbert I.
    CLINICAL COLORECTAL CANCER, 2011, 10 (03) : 210 - 216
  • [8] Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
    Bazarbashi, Shouki
    Aljubran, Ali
    Alzahrani, Ahmad
    Mohieldin, Ahmed
    Soudy, Hussein
    Shoukri, Mohammed
    CANCER MEDICINE, 2015, 4 (10): : 1505 - 1513
  • [9] PHASE II STUDY OF BEVACIZUMAB plus OXALIPLATIN PLUS CAPECITABINE FOLLOWED BY BEVACIZUMAB plus ERLOTINIB AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
    Munoz, A.
    Pericay, C.
    Llorente, B.
    Alonso, V
    Duenas, R.
    Roca, J.
    Rivera, F.
    Falco, E.
    Alvarez, I
    Salud, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 73 - 74
  • [10] Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer
    Munoz, Alberto
    Pericay, Caries
    Garcia-Giron, Carlos
    Alonso, Vicente
    Duenas, Rosario
    Cirera, Luis
    Rivera, Fernando
    Falco, Esther
    Alvarez Bustos, Inaki
    Salud, Antonieta
    ONCOLOGY RESEARCH, 2013, 21 (04) : 181 - 191
12345